+

WO2004039950A3 - Activation de lymphocytes specifiques du vhc - Google Patents

Activation de lymphocytes specifiques du vhc Download PDF

Info

Publication number
WO2004039950A3
WO2004039950A3 PCT/US2003/033610 US0333610W WO2004039950A3 WO 2004039950 A3 WO2004039950 A3 WO 2004039950A3 US 0333610 W US0333610 W US 0333610W WO 2004039950 A3 WO2004039950 A3 WO 2004039950A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
cells
specific
activation
specific cells
Prior art date
Application number
PCT/US2003/033610
Other languages
English (en)
Other versions
WO2004039950A2 (fr
Inventor
Michael Houghton
Steve Coates
Mark Selby
Xavier Paliard
Original Assignee
Chiron Corp
Michael Houghton
Steve Coates
Mark Selby
Xavier Paliard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Michael Houghton, Steve Coates, Mark Selby, Xavier Paliard filed Critical Chiron Corp
Priority to AU2003287188A priority Critical patent/AU2003287188A1/en
Priority to CA002505611A priority patent/CA2505611A1/fr
Priority to EP03781368A priority patent/EP1576125A4/fr
Publication of WO2004039950A2 publication Critical patent/WO2004039950A2/fr
Publication of WO2004039950A3 publication Critical patent/WO2004039950A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé d'activation de lymphocytes T spécifiques du virus de l'hépatite C (VHC), notamment des lymphocytes T CD4+ et CD8+. Les lymphocytes T spécifiques du VHC sont activés au moyen de protéines de fusion comprenant des polypeptides du VHC NS3, NS4, NS5a, et NS5b, des polynucléotides codant lesdites protéines de fusion, ou des compositions polypeptidiques ou polynucléotidiques contenant les composants individuels de ces fusions. Le procédé de l'invention peut être utilisé dans des systèmes modèles pour développer des compositions immunogènes spécifiques du VHC, ainsi que pour immuniser un mammifère contre le VHC.
PCT/US2003/033610 2002-10-25 2003-10-24 Activation de lymphocytes specifiques du vhc WO2004039950A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003287188A AU2003287188A1 (en) 2002-10-25 2003-10-24 Activation of hcv-specific cells
CA002505611A CA2505611A1 (fr) 2002-10-25 2003-10-24 Activation de lymphocytes specifiques du vhc
EP03781368A EP1576125A4 (fr) 2002-10-25 2003-10-24 Activation de lymphocytes specifiques du vhc

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28134102A 2002-10-25 2002-10-25
US10/281,341 2002-10-25

Publications (2)

Publication Number Publication Date
WO2004039950A2 WO2004039950A2 (fr) 2004-05-13
WO2004039950A3 true WO2004039950A3 (fr) 2007-11-22

Family

ID=32228760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033610 WO2004039950A2 (fr) 2002-10-25 2003-10-24 Activation de lymphocytes specifiques du vhc

Country Status (4)

Country Link
EP (1) EP1576125A4 (fr)
AU (1) AU2003287188A1 (fr)
CA (1) CA2505611A1 (fr)
WO (1) WO2004039950A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048630A1 (fr) 1999-02-17 2000-08-24 Csl Limited Complexes immunogenes et methodes y relatives
CN1809584B (zh) * 2003-04-25 2010-12-01 诺华疫苗和诊断公司 含有阳离子微粒和hcv e1e2 dna的组合物及其使用方法
CA2566725A1 (fr) * 2004-05-17 2005-12-01 Chiron Corporation Domaine ns5 du virus de l'hepatite c tronque et proteines hybrides comprenant ce dernier
NZ553244A (en) * 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
JP5474547B2 (ja) 2006-08-25 2014-04-16 ノバルティス アーゲー Ｈｃｖ融合ポリペプチド
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
CN103819565B (zh) * 2014-02-26 2016-11-09 广州万孚生物技术股份有限公司 Hcv重组融合抗原及其表达基因和制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038474A2 (fr) * 1995-05-31 1996-12-05 Bionova Corporation Diagnostic de et vaccination contre un virus a arn double brin positif a l'aide d'un polypeptide isole et non traite
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126460A (en) * 1996-05-24 2007-07-04 Novartis Vaccines & Diagnostic Multiple epitope fusion protein
AU2003248818A1 (en) * 2002-07-02 2004-01-23 Novartis Vaccines And Diagnostics, Inc. Hcv fusion proteins with modified ns3 domains

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
WO1996038474A2 (fr) * 1995-05-31 1996-12-05 Bionova Corporation Diagnostic de et vaccination contre un virus a arn double brin positif a l'aide d'un polypeptide isole et non traite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1576125A4 *

Also Published As

Publication number Publication date
WO2004039950A2 (fr) 2004-05-13
AU2003287188A1 (en) 2004-05-25
CA2505611A1 (fr) 2004-05-13
AU2003287188A8 (en) 2004-05-25
EP1576125A2 (fr) 2005-09-21
EP1576125A4 (fr) 2008-09-03

Similar Documents

Publication Publication Date Title
WO2001030812A3 (fr) Activation de lymphocytes t specifiques au virus de l'hepatite c
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
Muerhoff et al. Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis
Xu et al. Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication
Ryan et al. Virus-encoded proteinases of the Flaviviridae.
CA2303526A1 (fr) Systeme de culture du virus de l'hepatite c
SG165155A1 (en) Novel flavivirus antigens
WO2004005473A3 (fr) Proteines hybrides de vhc a domaines ns3 modifies
HK1112481A1 (en) Modified human hepatitis c virus genomic rna having autonomous replicative competence
JP2008516610A5 (fr)
WO2006096459A3 (fr) Virus infectieux chimeriques de l'hepatite c, leurs procedes de production et leurs methodes d'utilisation
EP0939128A3 (fr) Isolats de VHC
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
NZ518999A (en) Vaccine compositions
WO2009014216A1 (fr) Anticorps ayant une activité inhibitrice sur l'infection par le virus de l'hépatite c (vhc) et son utilisation
ATE376558T1 (de) Neues nichtstrukturelles hcv polypeptid
WO2004039950A3 (fr) Activation de lymphocytes specifiques du vhc
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
WO2004048402A3 (fr) Gene de fusion ns3/4a non structurel a codons optimises du virus de l'hepatite c
DK0644894T3 (da) Peptid til stimulering af Hepatitis C virus-specifikke cytotoksiske T-lymfocytter
Kim et al. Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein
JP2005532064A5 (fr)
WO1996038474A3 (fr) Diagnostic de et vaccination contre un virus a arn double brin positif a l'aide d'un polypeptide isole et non traite
WO2005113837A3 (fr) Domaine ns5 du virus de l'hepatite c tronque et proteines hybrides comprenant ce dernier
WO2008024518A3 (fr) Polypeptides de fusion du vhc

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2505611

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003781368

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003781368

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载